Docusign (NASDAQ:DOCU - Get Free Report) is anticipated to issue its Q2 2026 results before the market opens on Thursday, September 4th. Analysts expect the company to announce earnings of $0.84 per share and revenue of $780.3540 million for the quarter. Docusign has set its FY 2026 guidance at EPS. Q2 2026 guidance at EPS.Parties may review the information on the company's upcoming Q2 2026 earningreport for the latest details on the call scheduled for Thursday, September 4, 2025 at 5:00 PM ET.
Docusign (NASDAQ:DOCU - Get Free Report) last announced its quarterly earnings data on Thursday, June 5th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.81 by $0.09. Docusign had a return on equity of 14.27% and a net margin of 36.50%.The firm had revenue of $763.65 million for the quarter, compared to analyst estimates of $748.79 million. During the same period in the prior year, the company earned $0.82 EPS. The company's revenue was up 7.6% on a year-over-year basis. On average, analysts expect Docusign to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Docusign Price Performance
DOCU opened at $74.68 on Thursday. The stock's 50 day simple moving average is $75.37 and its 200 day simple moving average is $79.97. Docusign has a 1 year low of $54.31 and a 1 year high of $107.86. The firm has a market cap of $15.09 billion, a price-to-earnings ratio of 14.12, a PEG ratio of 27.06 and a beta of 1.01.
Docusign declared that its board has initiated a stock repurchase program on Thursday, June 5th that authorizes the company to buyback $1.00 billion in outstanding shares. This buyback authorization authorizes the company to purchase up to 6.6% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's board of directors believes its shares are undervalued.
Analyst Upgrades and Downgrades
Several equities analysts recently issued reports on DOCU shares. Robert W. Baird reduced their price target on Docusign from $93.00 to $85.00 and set a "neutral" rating on the stock in a research report on Friday, June 6th. JMP Securities restated a "market outperform" rating and issued a $124.00 target price on shares of Docusign in a research note on Tuesday, June 3rd. Bank of America reduced their price objective on Docusign from $88.00 to $85.00 and set a "neutral" rating for the company in a research report on Friday, June 6th. JPMorgan Chase & Co. reduced their price objective on Docusign from $81.00 to $77.00 and set a "neutral" rating for the company in a research report on Friday, June 6th. Finally, Wall Street Zen lowered Docusign from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Four equities research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $89.77.
Check Out Our Latest Analysis on DOCU
Insiders Place Their Bets
In related news, CFO Blake Jeffrey Grayson sold 15,143 shares of the business's stock in a transaction dated Wednesday, June 18th. The stock was sold at an average price of $74.80, for a total value of $1,132,696.40. Following the sale, the chief financial officer directly owned 110,723 shares in the company, valued at approximately $8,282,080.40. The trade was a 12.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Teresa Briggs sold 534 shares of the business's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $74.37, for a total value of $39,713.58. Following the completion of the sale, the director owned 8,805 shares in the company, valued at $654,827.85. This represents a 5.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 78,552 shares of company stock valued at $5,983,631 over the last three months. Insiders own 1.01% of the company's stock.
Institutional Investors Weigh In On Docusign
Large investors have recently added to or reduced their stakes in the stock. Rakuten Securities Inc. increased its stake in Docusign by 1,637.5% during the second quarter. Rakuten Securities Inc. now owns 973 shares of the company's stock worth $76,000 after acquiring an additional 917 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of Docusign in the second quarter valued at approximately $125,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Docusign by 76.6% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,105 shares of the company's stock valued at $164,000 after purchasing an additional 913 shares during the period. Smartleaf Asset Management LLC lifted its holdings in Docusign by 8.2% during the second quarter. Smartleaf Asset Management LLC now owns 2,169 shares of the company's stock worth $166,000 after buying an additional 165 shares during the period. Finally, Geneos Wealth Management Inc. lifted its holdings in Docusign by 28.5% during the second quarter. Geneos Wealth Management Inc. now owns 2,415 shares of the company's stock worth $188,000 after buying an additional 536 shares during the period. 77.64% of the stock is owned by institutional investors.
Docusign Company Profile
(
Get Free Report)
DocuSign, Inc provides electronic signature solution in the United States and internationally. The company provides e-signature solution that enables sending and signing of agreements on various devices; Contract Lifecycle Management (CLM), which automates workflows across the entire agreement process; Document Generation streamlines the process of generating new, custom agreements; and Gen for Salesforce, which allows sales representatives to automatically generate agreements with a few clicks from within Salesforce.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Docusign, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Docusign wasn't on the list.
While Docusign currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.